Table 3.

 Secondary outcomes for patients with neuropathic pain treated with nabilone or dihydrocodeine

Outcome measured	Number of patients analysed	Treatment effect (95% confidence interval)	P value
Available case analysis
Sleep	71	0.2 (−0.1 to 0.5)	0.20
Anxiety	70	−0.6 (−1.4 to 0.3)	0.19
Depression	70	−0.2 (−1.2 to 0.9)	0.72
Change in health	70	0.0 (−0.2 to 0.2)	0.88
Physical functioning	71	−1.2 (−4.5 to 2.1)	0.48
Social functioning	71	3.4 (−4.1 to 10.8)	0.37
Role, physical	69	8.9 (1.1 to 16.7)	0.03
Role, emotional	69	−1.2 (−11.8 to 9.5)	0.83
Mental health	71	2.5 (−2.7 to 7.6)	0.35
Vitality	71	−2.0 (−7.2 to 3.3)	0.46
Bodily pain	71	−5.2 (−10.1 to −0.4)	0.03
General health	70	0.8 (−3.1 to 4.6)	0.70
Per protocol analysis
Sleep	63	0.2 (−0.1 to 0.5)	0.28
Anxiety	62	−0.6 (−1.6 to 0.3)	0.18
Depression	62	−0.2 (−1.2 to 0.9)	0.78
Change in health	62	0.0 (−0.3 to 0.2)	0.76
Physical functioning	63	−1.4 (−5.1 to 2.4)	0.47
Social functioning	63	2.3 (−5.3 to 9.9)	0.54
Role, physical	62	10.8 (2.3 to 19.2)	0.01
Role, emotional	62	−0.6 (−11.4 to 10.2)	0.92
Mental health	63	2.0 (−3.2 to 7.1)	0.45
Vitality	63	−2.3 (−7.6 to 3.0)	0.39
Bodily pain	63	−5.7 (−10.9 to −0.5)	0.03
General health	63	0.5 (−3.7 to 4.7)	0.81

Positive values indicate higher scores with nabilone. Negative values indicate higher scores with dihydrocodeine.